Guido van Amerongen
Overview
Explore the profile of Guido van Amerongen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
den Heijer J, Kruithof A, van Amerongen G, de Kam M, Thijssen E, Grievink H, et al.
Br J Clin Pharmacol
. 2021 Feb;
87(9):3561-3573.
PMID: 33576113
Aims: A mutation in the GBA1 gene is the most common genetic risk factor for developing Parkinson's disease. GBA1 encodes the lysosomal enzyme glucosylceramidase beta (glucocerebrosidase, GCase) and mutations decrease...
2.
Siebenga P, van Amerongen G, Hay J, McDonnell A, Gorman D, Butt R, et al.
Clin Transl Sci
. 2019 Oct;
13(2):318-324.
PMID: 31642607
Sodium channel blockers are used for the treatment of pain, but this is limited by the lack of selectivity for different sodium channel subtypes, which can result in central nervous...
3.
van Amerongen G, Siebenga P, Gurrell R, Dua P, Whitlock M, Gorman D, et al.
Br J Anaesth
. 2019 Mar;
123(2):e194-e203.
PMID: 30915991
Background: This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel α2/α3/α5 gamma-aminobutyric acid A (GABA) subunit selective partial positive allosteric modulator (PAM),...
4.
Siebenga P, van Amerongen G, Okkerse P, Denney W, Dua P, Butt R, et al.
Eur J Pain
. 2019 Feb;
23(6):1129-1140.
PMID: 30793411
Background: Although reproducibility is considered essential for any method used in scientific research, it is investigated only rarely; thus, strikingly little has been published regarding the reproducibility of evoked pain...
5.
Brooks S, Jacobs G, de Boer P, Kent J, van Nueten L, van Amerongen G, et al.
J Psychopharmacol
. 2019 Jan;
33(2):202-209.
PMID: 30644312
Background: Insomnia is common in patients with major depressive disorder. Although antidepressants improve mood, insomnia often persists as a result of physiological hyperarousal. The orexin-2 receptor is increasingly being recognized...
6.
Siebenga P, van Amerongen G, Klaassen E, de Kam M, Rissmann R, Groeneveld G
Eur J Pain
. 2019 Jan;
23(5):874-883.
PMID: 30597682
Background: Pain models are commonly used in drug development to demonstrate analgesic activity in healthy subjects and should therefore not cause long-term adverse effects. The ultraviolet B (UVB) model is...
7.
Nickolls S, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown A, et al.
Br J Pharmacol
. 2017 Dec;
175(4):708-725.
PMID: 29214652
Background And Purpose: Benzodiazepines, non-selective positive allosteric modulators (PAMs) of GABA receptors, have significant side effects that limit their clinical utility. As many of these side effects are mediated by...
8.
Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, et al.
Br J Clin Pharmacol
. 2017 Nov;
84(2):301-309.
PMID: 29178434
Aim: Inhibitors of nerve growth factor (NGF) reduce pain in several chronic pain indications. NGF signals through tyrosine kinase receptors of the tropomyosin-related kinase (Trk) family and the unrelated p75...
9.
van de Loo A, Bervoets A, Mooren L, Bouwmeester N, Garssen J, Zuiker R, et al.
Psychopharmacology (Berl)
. 2017 Jul;
234(21):3175-3183.
PMID: 28755104
Rationale: The purpose of this study is to evaluate the single dose effect of intranasal esketamine (84 mg) compared to placebo on on-road driving performance. Mirtazapine (oral, 30 mg) was...
10.
van Amerongen G, Kanhai K, Baakman A, Heuberger J, Klaassen E, Beumer T, et al.
Clin Ther
. 2017 Feb;
40(9):1467-1482.
PMID: 28189366
Purpose: The aim of the present study was to evaluate the efficacy of an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) in patients with progressive multiple sclerosis (MS). Methods: This accelerated proof-of-concept...